261 related articles for article (PubMed ID: 31900481)
1. Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib.
Kroiss M; Megerle F; Kurlbaum M; Zimmermann S; Wendler J; Jimenez C; Lapa C; Quinkler M; Scherf-Clavel O; Habra MA; Fassnacht M
J Clin Endocrinol Metab; 2020 May; 105(5):1461-8. PubMed ID: 31900481
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial.
Campbell MT; Balderrama-Brondani V; Jimenez C; Tamsen G; Marcal LP; Varghese J; Shah AY; Long JP; Zhang M; Ochieng J; Haymaker C; Habra MA
Lancet Oncol; 2024 May; 25(5):649-657. PubMed ID: 38608694
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine.
Quinkler M; Hahner S; Wortmann S; Johanssen S; Adam P; Ritter C; Strasburger C; Allolio B; Fassnacht M
J Clin Endocrinol Metab; 2008 Jun; 93(6):2057-62. PubMed ID: 18334586
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
Habra MA; Stephen B; Campbell M; Hess K; Tapia C; Xu M; Rodon Ahnert J; Jimenez C; Lee JE; Perrier ND; Boraddus RR; Pant S; Subbiah V; Hong DS; Zarifa A; Fu S; Karp DD; Meric-Bernstam F; Naing A
J Immunother Cancer; 2019 Sep; 7(1):253. PubMed ID: 31533818
[TBL] [Abstract][Full Text] [Related]
5. Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide.
Kroiss M; Deutschbein T; Schlötelburg W; Ronchi CL; Neu B; Müller HH; Quinkler M; Hahner S; Heidemeier A; Fassnacht M;
Horm Cancer; 2016 Jun; 7(3):211-8. PubMed ID: 26961793
[TBL] [Abstract][Full Text] [Related]
6. Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma.
Megerle F; Herrmann W; Schloetelburg W; Ronchi CL; Pulzer A; Quinkler M; Beuschlein F; Hahner S; Kroiss M; Fassnacht M;
J Clin Endocrinol Metab; 2018 Apr; 103(4):1686-1695. PubMed ID: 29452402
[TBL] [Abstract][Full Text] [Related]
7. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
8. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
Lerario AM; Worden FP; Ramm CA; Hesseltine EA; Stadler WM; Else T; Shah MH; Agamah E; Rao K; Hammer GD
Horm Cancer; 2014 Aug; 5(4):232-9. PubMed ID: 24849545
[TBL] [Abstract][Full Text] [Related]
9. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.
Weigand I; Altieri B; Lacombe AMF; Basile V; Kircher S; Landwehr LS; Schreiner J; Zerbini MCN; Ronchi CL; Megerle F; Berruti A; Canu L; Volante M; Paiva I; Della Casa S; Sbiera S; Fassnacht M; Fragoso MCBV; Terzolo M; Kroiss M
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32449514
[TBL] [Abstract][Full Text] [Related]
10. Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer?
Wierman ME
Lancet Oncol; 2024 May; 25(5):534-535. PubMed ID: 38608692
[No Abstract] [Full Text] [Related]
11. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.
Kroiss M; Quinkler M; Johanssen S; van Erp NP; Lankheet N; Pöllinger A; Laubner K; Strasburger CJ; Hahner S; Müller HH; Allolio B; Fassnacht M
J Clin Endocrinol Metab; 2012 Oct; 97(10):3495-503. PubMed ID: 22837187
[TBL] [Abstract][Full Text] [Related]
13. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
14. Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma.
Boilève A; Mathy E; Roux C; Faron M; Hadoux J; Tselikas L; Al Ghuzlan A; Hescot S; Leboulleux S; de Baere T; Lamartina L; Deschamps F; Baudin E
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4698-e4707. PubMed ID: 34143888
[TBL] [Abstract][Full Text] [Related]
15. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.
Fassnacht M; Johanssen S; Fenske W; Weismann D; Agha A; Beuschlein F; Führer D; Jurowich C; Quinkler M; Petersenn S; Spahn M; Hahner S; Allolio B;
J Clin Endocrinol Metab; 2010 Nov; 95(11):4925-32. PubMed ID: 20668036
[TBL] [Abstract][Full Text] [Related]
16. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A
Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.
Berruti A; Sperone P; Ferrero A; Germano A; Ardito A; Priola AM; De Francia S; Volante M; Daffara F; Generali D; Leboulleux S; Perotti P; Baudin E; Papotti M; Terzolo M
Eur J Endocrinol; 2012 Mar; 166(3):451-8. PubMed ID: 22189997
[TBL] [Abstract][Full Text] [Related]
18. Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy.
Bednarski BK; Habra MA; Phan A; Milton DR; Wood C; Vauthey N; Evans DB; Katz MH; Ng CS; Perrier ND; Lee JE; Grubbs EG
World J Surg; 2014 Jun; 38(6):1318-27. PubMed ID: 24615603
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH
J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
Kerkhofs TM; Baudin E; Terzolo M; Allolio B; Chadarevian R; Mueller HH; Skogseid B; Leboulleux S; Mantero F; Haak HR; Fassnacht M
J Clin Endocrinol Metab; 2013 Dec; 98(12):4759-67. PubMed ID: 24057287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
